louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04567446: Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach
Official title: Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cancer
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor class: OTHER
First posted: 2020-09-28
Enrollment: 1100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patient with cancer who will start treatment anticancer

Brief summary: Multicentric prospective study with collection of biological samples as part of type II research


Eligibility criteria: Inclusion Criteria:

* Patient with cancer who will start treatment anticancer (see cohorts).
* Patient information and signature of the consent form before any specific procedure for the study. The patient must be able and must be inclined to cooperate in the study procedures.
* Patient affiliated to a social security scheme or beneficiary of a similar scheme.

Exclusion Criteria:

* Pregnant or lactating woman
* Patient under guardianship or curatorship or deprived of liberty by a decision judicial or administrative or patient unable to give his consent.

Primary outcomes:
measure: Overall survival
timeFrame: Up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Villejuif
country: France
facility: Gustave Roussy
state: Val De Marne
city: Aix-en-Provence
country: France
facility: Centre hospitalier du Pays d'Aix
city: Beuvry
country: France
facility: Centre Pierre Curie
city: Coudekerque-Branche
country: France
facility: Clinique du Flandre
city: Lille
country: France
facility: CHRU Lille - Hôpital Calmette
city: Lyon
country: France
facility: Centre Léon Bérard
city: Paris
country: France
facility: Hôpital St Louis
city: Suresnes
country: France
facility: Hôpital Foch
city: Toulon
country: France
facility: Centre hospitalier TOULON - Sainte-Musse
Study officials:
References:
Clinical trial NCT05889546: Rapid Autopsy Protocol for Patients with Small Cell Lung Cancer
Official title: Rapid ("Warm") Autopsy Protocol for Patients with Small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Small Cell Lung Cancer
Keywords: Lung Cancer
Small Cell Lung Cancer
Future Research
Lead sponsor: Indiana University
Sponsor class: OTHER
First posted: 2023-06-05
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patient with active SCLC being seen at IUSCCC clinics.

Brief summary: This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection.

Detailed description: The goal of this project to establish a rapid autopsy program in SCLC at the IUSCCC and outline the key components necessary for tumor tissue acquisition. This proposal is a collaboration between scientists, lung cancer physicians, pathologists, and the IUSCCC Translational Research Core. Tumor tissue collected will be used for protein and gene analysis and RNA, whole exome sequencing in addition to the establishment of SCLC. This research is part of a discovery project in which biological and molecular markers of SCLC will be identified.

Eligibility criteria: Inclusion Criteria:

1. ≥ 18 years old at the time of informed consent
2. Written informed consent and HIPAA authorization for release of personal health information.
3. Active SCLC diagnosis.

Primary outcomes:
measure: Determining the Feasibility of the Creation of a Rapid Autopsy Program at IUSCCC for SCLC through enrollment and sample collections
timeFrame: 5 years
measure: Utilization of Tissue to Better Understand the Complex Biology of SCLC
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Indiana University Melvin and Bren Simon Comprehensive Cancer Center
state: Indiana
city: Indianapolis
country: United States
facility: Roudebush VA Medical Center
state: Indiana
city: Indianapolis
country: United States
facility: Sidney and Lois Eskenazi Hospital
state: Indiana
Study officials:
affiliation: Indiana University
name: Shadia I. Jalal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04287946: Endovascular GSN Ablation in Subjects With HFpEF
Official title: Endovascular Ablation of the Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction - First In-human Feasibility Study
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Heart Failure With Preserved Ejection Fraction
Keywords: Heart Failure
Preserved Ejection Fraction
Lead sponsor: Axon Therapies, Inc.
Sponsor class: INDUSTRY
First posted: 2020-02-27
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and potential benefits of single-side block of a nerve that connects to the intestines, liver and spleen called the "greater splanchnic nerve" for the treatments of patients with symptomatic heart failure who have normal pumping of the heart. The study will be performed in patients whose heart failure is not responding well to standard treatments and remain symptomatic.


Eligibility criteria: Key Inclusion Criteria:

* Chronic heart failure
* Transthoracic echocardiographic evidence of diastolic dysfunction
* Ongoing stable GDMT HF management and management of potential comorbidities
* LVEF ≥50% in the past 3 months

Key Exclusion Criteria:

* Cardiac resynchronization therapy initiated within the past 6 months
* Advanced heart failure
* Admission for HF within the past 30 days
* Presence of significant valve disease
* Mean right atrial pressure (RAP) \>20mmHg during hemodynamic screening

Primary outcomes:
measure: Composite incidence of one or more of the following: major adverse cardiac, cerebrovascular embolic, or renal event (MACCRE)
timeFrame: 1 month
measure: Mean change of PCWP with exercise after index procedure ablation as compared to baseline
timeFrame: 1 month
Secondary outcomes:
measure: Incidence of MACCRE, all serious adverse events, all-cause mortality, CV mortality and HF related mortality
timeFrame: 6 month
measure: Change in average PCWP as compared to baseline
timeFrame: 1 month
measure: Secondary Efficacy Endpoint
timeFrame: 1, 3, 6 months
measure: Secondary Efficacy Endpoint
timeFrame: 1, 3, 6 months
Other outcomes:
Locations:
city: Praha
country: Czechia
facility: Nemocnice Na Homolce
city: Tbilisi
country: Georgia
facility: Tbilisi Heart and Vascular Clinic
city: Tbilisi
country: Georgia
facility: Tbilisi Heart Center
Study officials:
affiliation: Coridea, Inc.
name: Howard Levin, MD
role: STUDY_CHAIR
References:
citation: Fudim M, Zirakashvili T, Shaburishvili N, Shaishmelashvili G, Sievert H, Sievert K, Reddy VY, Engelman ZJ, Burkhoff D, Shaburishvili T, Shah SJ. Transvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction: First-in-Human Study. JACC Heart Fail. 2022 Oct;10(10):744-752. doi: 10.1016/j.jchf.2022.05.009. Epub 2022 Jul 6.
Clinical trial NCT00761046: Retrospective Study on Cenos Stem With BoneMaster HA
Official title: Retrospective Study on Cenos Stem With BoneMaster HA
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Osteoarthritis
Lead sponsor: Zimmer Biomet
Sponsor class: INDUSTRY
First posted: 2008-09-26
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients Who Received CENOS prosthesis for Intended Uses

Brief summary: Retrospective data collection of the CENOS implant comparing with and without BoneMaster HA coatings.

Detailed description: Not applicable as study was withdrawn

Eligibility criteria: Patients Who Received CENOS prosthesis for Intended Uses

Primary outcomes:
measure: Complication Rate
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00152646: Platelets Induced Vasodilation, in Vitro and in Vivo Study
Official title: Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Peripheral Arterial Disease
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2005-09-09
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of the study is to show the implication of platelets in vasodilation using in vivo and in vitro analysis and to compare the effects of placebo, aspirin and Clopidogrel in this interaction platelets/vessels.

The effects of 7 days of each treatment will be compared in healthy subjects and patients with arteriopathy.


Eligibility criteria: Inclusion Criteria:

Inclusion criteria healthy subjects

* Man or Woman 18 years
* Agreement signed
* French health insurance
* Able to understand the study
* Biological haemostatic test normal
* Vascular Doppler of lower limbs normal
* Pressure index \> 1 in both lower limbs

Inclusion criteria healthy subjects

* Man or Woman 18 years
* Agreement signed
* French health insurance
* Able to understand the study
* Biological haemostatic test normal
* Lower limbs arteriopathy (clinical, pressure index, Doppler)

Exclusion Criteria:

* Unable to sign agreement
* Subjects protected by low
* Participation to other study
* Changes of treatment within the 15 days before inclusion
* Chronic treatment with Clopidogrel or drugs against inflammation
* Severe respiratory, cardiac, kidney, hepatic insufficiency
* Haemostatic troubles
* Diabetic neuropathy
* Neurologic desease (Parkinson.....)
* Hypertension
* Symptomatic stomach ulcer
* Anaemia Hb\<11g/l
* Pregnant women or breast feeding

Primary outcomes:
measure: In vivo vasodilation induced by low intensity current
measure: In vitro study of platelets function
measure: In vitro vasodilation induced by platelets in isolated rat's vessels
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: Exploration Fonctionnelles Vasculaires
state: Maine et Loire
Study officials:
affiliation: University Hospital, Angers
name: Marc Antoine Custaud, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01346046: Evaluation of SCOUT DS in Subjects With Type 2 Diabetes #2
Official title: An Evaluation of a Noninvasive Diabetes Screening Device in Subjects at the TCOYD Diabetes Conference
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus, Non-Insulin Dependent
Keywords: Type 2 Diabetes
Adults 18 years and older
Taking Control of Your Diabetes Health Fair
Lead sponsor: VeraLight, Inc.
Sponsor class: INDUSTRY
First posted: 2011-05-02
Enrollment: 264
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Attendees of the Taking Control of Your Diabetes Health Fair, Albuquerque Convention Center

Brief summary: The primary objective of the trial is to collect SCOUT DS and Hemoglobin A1c measurements of subjects who have been diagnosed with Type 2 diabetes.

Detailed description: Previous studies have excluded subjects with Type 2 diabetes. The primary objective of this study is to correct an imbalance in the disease prevalence of the data set used to develop the SCOUT DS diabetes screening algorithm.

Eligibility criteria: Inclusion Criteria:

* Age greater than or equal to 18 years Self-reported diagnosis of type 2 diabetes No Self-reported diagnosis of type 2 diabetes

Exclusion Criteria:

* Less than 18 years of age

  * Diagnosed with type 1 diabetes
  * Known to be pregnant (Self Reported)
  * Receiving dialysis or having known renal compromise
  * Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm.
  * Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)

Primary outcomes:
measure: Continuing validation of SCOUT DS algorithm
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: Albuquerque Convention Center
state: New Mexico
Study officials:
affiliation: Lovelace Scientific Resources
name: Walter Forman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01659346: Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.
Official title: A Prospective Randomized Controlled Trial Comparing Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Hepatocellular Carcinoma With Portal Vein Thrombosis
Lead sponsor: Institute of Liver and Biliary Sciences, India
Sponsor class: OTHER
First posted: 2012-08-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Every patient with HCC (Hepato-Cellular Carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic variceal ligation. They will be followed to assess the rate of reduction of index bleed rate as well as survival difference between the groups.


Eligibility criteria: Inclusion Criteria:

* Patients of cirrhosis with Hepatocellular carcinoma and portal vein thrombosis
* Presence of large oesophageal varices or small with high risk

Exclusion Criteria:

* Any contra-indication to beta-blockers
* Any Endoscopic Variceal Ligation or Sclerotherapy within last 3 months
* High risk gastric varices
* Any past history of Transhepatic Intrajugular Portosystemic Shunt or surgery for portal hypertension
* Significant cardio or pulmonary co-morbidity
* Any extrahepatic malignancy
* Patients with past history of variceal bleed
* Patients with non-tumor portal vein thrombosis
* Refusal to participate in the study

Primary outcomes:
measure: First Variceal Bleeding
timeFrame: 1.5 years
Secondary outcomes:
measure: Death
timeFrame: 1.5 years
measure: Procedure related complications.
timeFrame: 1.5 years
measure: Reappearance of Esophageal varices in presence of Portal Vein Thrombosis
timeFrame: 1.5 years
Other outcomes:
Locations:
city: New Delhi
country: India
facility: Institute of Liver and Biliary Sciences
state: Delhi
Study officials:
affiliation: Institute of Liver and Biliary Sciences
name: Dr Shakti P Choudhury, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00563446: Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia
Official title: Conversion From Once Weekly Recombinant Human Erythropoietin to Once Monthly Darbepoetin Alfa for the Treatment of Renal Anemia in Continuous Ambulatory Peritoneal Dialysis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anemia
Kidney Failure, Chronic
Peritoneal Dialysis, Continuous Ambulatory
Keywords: Anemia
End-stage renal failure
Continuous ambulatory peritoneal dialysis
Lead sponsor: Hospital Authority, Hong Kong
Sponsor class: OTHER_GOV
Collaborators: name: Kirin Pharmaceutical (Asia) CO., LTD
First posted: 2007-11-26
Enrollment: 16
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Anaemia is a common consequence of chronic renal failure. Darbepoetin alfa is a unique erythropoietic protein that stimulates erythropoiesis by the same mechanism as endogenous erythropietin and conventional recombinant human erythropoietin (rHuEPO). Darbepoetin alfa has been shown to have a serum half-life 3-fold longer than that of rHuEPO, which allows dosing at extended intervals and less frequent injection.

The objective is to evaluate the efficacy and safety of darbepoetin alfa therapy given at an extended once monthly dosing interval in the treatment of renal anaemia in continuous ambulatory peritoneal dialysis.


Eligibility criteria: Inclusion Criteria:

* Patients on continuous ambulatory peritoneal dialysis
* Patients receiving subcutaneous recombinant human erythropoietin (rHuEPO)
* Patients with haemoglobin level ?10 g/dL and remain stable for the past 3 months while receiving rHuEPO

Exclusion Criteria:

* Uncontrolled hypertension
* Severe congestive heart failure (NYHA class III or IV)
* Grand mal epilepsy
* Any kind of blood loss causing Fe depletion
* Presence of infection, either acute or chronic, or inflammatory conditions within 3 months preceding the study
* Malignancy
* Aluminum toxicity
* Severe hyperparathyroidism with marrow fibrosis or osteitis fibrosa _ PTH \> 20 times of normal
* Vitamin B12 or folate deficiency _ MCV \> 100fL
* Haemolysis
* Marrow dysfunction e.g. aplastic anaemia, myelodysplastic syndrome, multiple myeloma, etc
* Thalassaemia major, intermediate or minor, or red cell enzyme defects
* Blood transfusion within 3 months preceding the study
* Pregnancy or lactating mothers

Primary outcomes:
measure: Hemoglobin level
timeFrame: Over 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Princess Margaret Hospital
Study officials:
affiliation: Division of Nephrology, Medicine & Geriatrics, Princess Margaret Hospital
name: Samuel KS Fung, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06094946: Parturient Satisfaction With Epidural Analgesia by PCEA or Manual Boluses
Official title: Parturient Satisfaction With Epidural Analgesia During Parturient Controlled Pump
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Labor Pain
Keywords: epidural analgesia
labour epidural
patient controlled epidural
Lead sponsor: Women's Hospital HUS
Sponsor class: OTHER
Collaborators: name: Helsinki University Central Hospital
First posted: 2023-10-23
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Parturients coming to the delivery hospital (a tertiary delivery hospital with 8000 deliveries per year and 85 % epidural rate) for intended vaginal delivery and requesting epidural analgesia

Brief summary: Those prospective parturients that express that they may want an epidural labour analgesia for their delivery will be informed about the possibility to choose between a pump driven epidural or midwife administered intermittent boluses.

Detailed description: The purpose is to compare parturient and midwife satisfaction with the epidural labour analgesia when epidural analgesia is maintained by an epidural bolus pump (automated mandatory boluses with patient controlled boluses without background infusion) or midwife administered on-demand boluses.

Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Admitted to the delivery hospital with the prospect of vaginal delivery
* On admission when questioned about planned analgesia expresses that may want an epidural analgesia for the planned vaginal delivery
* After reading the study prochure signs the participation (consent) form
* Sufficient command of Finnish or Swedish to facilitate interview

Exclusion Criteria:

* Contraindications for epidural analgesia
* Planned cesarean delivery
* Age under 18 years

Primary outcomes:
measure: Parturient satisfaction with analgesia
timeFrame: During use of labour analgesia (up to 6 hours)
Secondary outcomes:
measure: Midwife satisfaction with epidural labour analgesia
timeFrame: During use of labour analgesia (up to 6 hours)
measure: Support person's satisfaction with epidural labour analgesia
timeFrame: During use of labour analgesia (up to 6 hours)
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: HUS/Women's hospital dept of anaesthesia
Study officials:
affiliation: Helsinki University Hospital Women's hospital
name: Riina Jernman, MD PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01061346: Effect of Dietary Fat When Eaten With Fructose Versus Glucose
Official title: Effect of Dietary Fat When Eaten With Fructose vs. Glucose on Insulin Resistance and Liver Fat
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Body Weight Changes
Keywords: Fructose
Glucose
Lead sponsor: Pennington Biomedical Research Center
Sponsor class: OTHER
Collaborators: name: USDA Beltsville Human Nutrition Research Center
First posted: 2010-02-03
Enrollment: 19
Sex: ALL
Minimum age (years): 28
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is designed to test the effects on liver fat of varying fat intake in the presence of fructose or glucose. We hypothesize that higher dietary fat when eaten with fructose as compared to glucose will increase the amount of hepatic lipid as measured by magnetic resonance spectroscopy.

Detailed description: After 2 screening visits including an exercise test, DEXA and CT scan, qualifiers begin a 7 day diet with 20% fat, 65% carbohydrate (with 20% glucose) and 15 % protein. Participants consume 2 meals per day at PBRC with lunch and weekend meals packed to go. Following a test day, participants are randomized to one of 3 diet assignments and then test again:

1)20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein 2)40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein 3)40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein On Day 7 and again 14 days later participants have labs, an oral Glucose tolerance test, hepatic and intramuscular lipid measures by MRS, vital signs and waist measurement.

Eligibility criteria: Inclusion Criteria:

* BMI between 25 and 35 kg/m2 inclusive
* At least one of the following:

  1. Impaired fasting glucose between 100-125 mg/dl inclusive
  2. HDL below 40 mg/dl for men or below 50 mg/dl for females
  3. Triglycerides between 150 mg/dl and 400 mg/dl inclusive
  4. Blood pressure above or equal to 135 / 85 mm Hg
* Waist circumference \>94cm (37 inches) for men or \>80cm for women
* Mainly Healthy

Exclusion Criteria:

* Unable or unlikely to eat study foods and only foods provided by PRBC
* Taking routine medications except birth control pills
* Smoke, Abuse drugs,or Alcohol
* Pregnant or breastfeeding, irregular menstrual cycles, Post-menopausal,or PCOS
* Diabetes, heart, lung, liver, blood, or Kidney disease

Primary outcomes:
measure: Evidence to determine whether intake in beverages that provide 20% fructose or a similar beverage made with glucose given with a higher fat diet has an effect on your body weight, blood pressure, fats in your liver or your blood sugar.
timeFrame: One Month
Secondary outcomes:
Other outcomes:
Locations:
city: Baton Rouge
country: United States
facility: Pennintgon Biomedical Research Center
state: Louisiana
Study officials:
affiliation: Pennington Biomedical Research Center
name: George A Bray, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Pennington Biomedical Research Center
name: Sudip Bajpcyi, PhD
role: STUDY_CHAIR
References: